James Siegler, MD

Articles by James Siegler, MD

Place of Factor XI Inhibitors in Stroke Prevention in Clinical Practice

ByAshkan Shoamanesh, MD, FRCPC, FESO,Gregory W. Albers, MD,James Siegler, MD,Eva Mistry, MD

March 24th 2026

Experts weigh factor XIa inhibitor asundexian after ischemic stroke, highlighting strong efficacy and safety signals and fueling optimism for Librexia Stroke trial results.

Sub-group Analysis of OCEANIC-STROKE Trial for Secondary Stroke Prevention

ByAshkan Shoamanesh, MD, FRCPC, FESO,Gregory W. Albers, MD,James Siegler, MD,Eva Mistry, MD

March 24th 2026

Global trial tests ascendexian after ischemic stroke/TIA, showing low bleeding and raising questions about diversity and real-world fit.

Results of OCEANIC-STROKE Trial for Secondary Stroke Prevention

ByAshkan Shoamanesh, MD, FRCPC, FESO,Gregory W. Albers, MD,James Siegler, MD,Eva Mistry, MD

March 17th 2026

Global trial tests ascendexian after ischemic stroke/TIA, showing low bleeding and raising questions about diversity and real-world fit.

Asundexian and Study Design of OCEANIC-STROKE Trial for Secondary Stroke Prevention

ByAshkan Shoamanesh, MD, FRCPC, FESO,Gregory W. Albers, MD,James Siegler, MD,Eva Mistry, MD

March 17th 2026

Experts unpack a global stroke-prevention trial, weighing real-world fit, diversity gaps, reperfusion patients, and surprisingly low bleeding.

Mechanism of Action of Factor XI Inhibitors

ByAshkan Shoamanesh, MD, FRCPC, FESO,Gregory W. Albers, MD,James Siegler, MD,Eva Mistry, MD

March 10th 2026

Experts explain how factor XIa inhibitors may prevent post‑stroke clots while sparing hemostasis, offering safer anticoagulation ahead of Phase III.

Factor XI Inhibitors for Stroke Prevention

ByAshkan Shoamanesh, MD, FRCPC, FESO,Gregory W. Albers, MD,James Siegler, MD,Eva Mistry, MD

March 10th 2026

Experts explain why lowering blood pressure below 130/80 cuts stroke risk, and share practical tips on adherence, apps, and polypill therapy.

Hypertension Management and Secondary Stroke Prevention

ByAshkan Shoamanesh, MD, FRCPC, FESO,Gregory W. Albers, MD,James Siegler, MD,Eva Mistry, MD

March 3rd 2026

New stroke-prevention guidance urges early dual antiplatelets for minor stroke/TIA, faster anticoagulation for AF, and LDL targets plus diet focus.

AHA Recommendations for Secondary Stroke Prevention

ByAshkan Shoamanesh, MD, FRCPC, FESO,Gregory W. Albers, MD,James Siegler, MD,Eva Mistry, MD

March 3rd 2026

Clinicians tailor secondary stroke prevention talks by cause, literacy, and resources—boosting adherence through risk-factor coaching, shared decisions, and affordable antithrombotics.

Stroke Prevention Strategies, Patient Communication, and Shared Decision Making

ByAshkan Shoamanesh, MD, FRCPC, FESO,Gregory W. Albers, MD,James Siegler, MD,Eva Mistry, MD

February 24th 2026

Clinicians explain secondary stroke prevention by tailoring education, addressing risk factors, and choosing affordable antithrombotic plans through shared decision-making to boost adherence.

Secondary Stroke Prevention Strategies at System Level

ByAshkan Shoamanesh, MD, FRCPC, FESO,Gregory W. Albers, MD,James Siegler, MD,Eva Mistry, MD

February 24th 2026

Stroke recurrence risk peaks in the first days after TIA or minor stroke, driving rapid evaluation and tailored prevention strategies like short-term dual antiplatelet therapy.